Drug Discovery@nature.com 30 September 2011

Advertisement Accelrys Discovery Studio 3.1 - a comprehensive portfolio of validated scientific technologies for both small molecule and macromolecule-based research. Now includes tools to predict protein-protein aggregation in biological therapeutics. Discovery Studio meets the modeling, automation and collaboration challenges faced by scientists today. Learn more by registering for our webinar series TABLE OF CONTENTS 30 September 2011 News Analysis Research Highlights Research & Reviews Careers Advertisement DISCOVER HIDDEN OPPORTUNITIES IN THE PIPELINE Thomson Reuters Cortellis™: drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, intuitively presented. So you can make the most informed decision for growth, and stay ahead of the competition. Start your free Cortellis trial today. Find out more at:  http://science.thomsonreuters.com/sneakpreview/?s=NatureBio Nature Reviews Drug Discovery is on Twitter Advertisement Now Live - a new multidisciplinary research journal from the publishers of Nature   Online and open access, Scientific Reports provides rapid publication and high visibility of research - for all areas of science. All papers accepted for publication are technically sound, without any requirement for impact.  Submit your next paper to Scientific Reports   News Top Cheap drugs pulled despite wealth gap in middle-income countries doi:10.1038/nm0911-1023 According to some experts, the growing wealth of many developing countries means that many people will be unable to afford medicine under the current scheme of basing prices on average per-capita income levels by country. Full Text Proposed centralization of trial oversight stirs mixed reaction doi:10.1038/nm0911-1025 The proposal by the Department of Health and Human Services that multisite studies conducted in the US should each be overseen by a single institutional review board for that study has been met with both support and concern. Full Text FDA reorganization inspires hope for better coordination doi:10.1038/nm0911-1024b The FDA’s newly created Office of Medical Products and Tobacco, directed by Stephen Spielberg, should help the agency to better coordinate interactions between its centers for drug, biologics, medical devices and tobacco products. Full Text Vaccine campaign to target deadly childhood diarrhoea doi:10.1038/477519a Programme to guard against second-biggest killer of under-fives rolls out across Africa. Full Text Analysis Top Finding the repurpose doi:10.1038/scibx.2011.1030 NuMedii Inc., a bioinformatics spinout from Stanford, is planning to use a new computational approach to predict the potential of existing drugs to treat new indications; the approach has already provided data to support two drug repurposing opportunities. Full Text Identifying R&D outliers doi:10.1038/nrd3555 Although the average ability of pharmaceutical R&D to create value has declined, there is in fact a large variation in R&D performance across the industry. This article presents an analysis identifying companies — termed 'outliers' —that seem to have been more successful in counteracting the overall industry trend of declining R&D productivity. Full Text Belatacept doi:10.1038/nrd3536 In June 2011, belatacept (Nulojix; Bristol-Myers Squibb), a fusion protein that inhibits T cell activation by binding to CD80 and CD86, was approved by the US FDA for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Full Text Research Highlights Top Selective oxycution? doi:10.1038/nrd3543 A new study demonstrates that the natural product piperlongumine may have promising cancer-specific cytotoxicity. Full Text Rescuing age-related memory loss doi:10.1038/nrn3096 Arnsten and colleagues provide new insight into the physiological basis of age-related memory decline and a potential means to restore function. Full Text Vaccines: Structure-based design doi:10.1038/nrd3539 Vaccination with a chimeric antigen developed using a structure-based strategy provides broad protection against multiple variants of the pathogen that causes meningitis. Full Text Research & Reviews Top Targeting cancer metabolism: a therapeutic window opens doi:10.1038/nrd3504 Cancer cells have adapted metabolically to support their characteristic high rate of proliferation. This review discusses how the metabolic differences between cancer cells and normal cells could be therapeutically targeted. Full Text Minimum information about a bioactive entity (MIABE) doi:10.1038/nrd3503 This article proposes reporting guidelines for bioactive entities, developed by representatives from industry, academia and data resource providers, which could aid the analysis of data to provide insight for developing improved molecules. Full Text Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner doi:10.1038/nm.2378 Pajvani and colleagues report a new role of Notch in glucose metabolism, and suggest that Notch inhibition could be beneficial in diabetes. Full Text The transcription factor FOXM1 is a cellular target of the natural product thiostrepton doi:10.1038/nchem.1114 This paper shows that thiostrepton, which has anticancer properties, binds to FOXM1, preventing its interaction with several gene promoters. This illustrates the druggability of transcription factors, and provides a molecular basis for targeting FOXM1. Full Text Drug Discovery JOBS of the week A Postdoctoral Fellow Position in Research of Filoviruses University of Texas Medical Branch - Galveston National Lab Galveston, US Lecturer (Fixed Term) in Bioinformatics National University of Ireland, Galway Galway, IE Postdoctoral Position - Biochemistry and Cell Biology Stony Brook University Stony Brook, US Team Leaders in Computational Genomics The Institute of Cancer Research London, GB Faculty Positions Cancer Institute of New Jersey New Brunswick, US More Science jobs from Drug Discovery EVENT 5th Vaccine and ISV Annual Global Congress 02.-04.10.11 Seattle, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.